RecruitingPhase 2NCT07279714
Fisetin in Mild Alzheimer's Disease
Fisetin Intervention Study in Mild Alzheimer's Disease
Sponsor
Sunnybrook Health Sciences Centre
Enrollment
5 participants
Start Date
Jan 27, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.
Eligibility
Min Age: 60 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying Fisetin for people with alzheimer dementia, alzheimer dementia (ad), and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 60 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERFisetin
Fisetin 20mg/kg/day
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07279714
Related Trials
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
NCT0684732140 locations
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
NCT043968731 location
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
NCT0759967011 locations
Identifying Biomarkers in Alzheimer's Disease
NCT056556501 location